Humacyte Announces Six Presentations Scheduled for the Upcoming 52nd Annual Symposium on Vascular and Endovascular Issues, Techniques and Horizons (VEITHsymposium)

Rhea-AI Summary

Humacyte (Nasdaq: HUMA) announced six presentations on its Acellular Tissue Engineered Vessel (ATEV™) at the 52nd Annual VEITHsymposium in New York, November 18-22, 2025. The sessions detail clinical use and histologic evaluation of ATEV across vascular indications, including trauma, dialysis access, distal revascularization, and randomized trial outcomes.

Presentations scheduled for November 19 and 20, 2025, include two-year outcome data versus autologous vein grafts and fistulas, case reports from the CLN-PRO-V005 trial, female-specific two-year randomized trial outcomes, long-term histologic regeneration data, and a review of published outcomes across multiple vascular indications.

DURHAM, N.C., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced the details of six presentations on the Company’s acellular tissue engineered vessel (ATEV™) that are scheduled for the 52nd Annual Symposium on Vascular and Endovascular Issues, Techniques And Horizons (VEITHsymposium), to be held November 18-22, 2025 in New York, NY. The VEITHsymposium is a premier educational event for vascular surgeons, interventional radiologists, interventional cardiologists, and other vascular specialists.

Details of the presentations are as follows:

Wednesday, November 19, 2025 – Podium Session 5

“Human Acellular Vessels vs. Autologous Vein Grafts for Combat Vascular Trauma: Two-Year Outcomes from the War in Ukraine,” to be presented by Oleksander V. Sokolov, MD, PhD

“Use of the Acellular Tissue Engineered Vessel for Torso Arterial Trauma: Case Reports from the CLN-PRO-V005 Trial,” to be presented by Gregory A. Magee, MD, MSc

“Use of the Acellular Tissue Engineered Vessel (ATEV™) in Distal Revascularization and Interval Ligation (DRIL) Procedures for Dialysis Access-Associated Steal Syndrome: Case Series from the CLN-PRO-V005,” to be presented by Ernest E. Moore, MD

“Two-Year Outcomes in Female Patients from A Prospective Randomized Trial of Humacyte’s Acellular Tissue Engineered Vessel vs. Autologous Arteriovenous Fistula for Hemodialysis,” to be presented by Mohamad A. Hussain, MD, PhD

“In Vivo Regeneration of Bioengineered Blood Vessels: Histologic Evaluation of Acellular Tissue Engineered Vessels After Long-Term Clinical Use,” to be presented by Luigi Pascarella, MD

Thursday, November 20, 2025 – Podium Session 8

“Clinical Effectiveness of An Acellular Tissue Engineered Vessel: Review of Published Outcomes Across Multiple Vascular Indications,” to be presented by Michael Curi, MD

About Humacyte

Humacyte, Inc. (Nasdaq: HUMA) is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues, advanced tissue constructs, and organ systems designed to improve the lives of patients and transform the practice of medicine. The Company develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Humacyte’s Biologics License Application for the acellular tissue engineered vessel (ATEV) in the vascular trauma indication was approved by the FDA in December 2024. ATEVs are also currently in late-stage clinical trials targeting other vascular applications, including arteriovenous (AV) access for hemodialysis and peripheral artery disease (PAD). Preclinical development is also underway in coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple novel cell and tissue applications. Humacyte’s 6mm ATEV for AV access in hemodialysis was the first product candidate to receive the FDA’s Regenerative Medicine Advanced Therapy (RMAT) designation and has also received FDA Fast Track designation. Humacyte’s 6mm ATEV for urgent arterial repair following extremity vascular trauma and for advanced PAD also have received RMAT designations. The ATEV received priority designation for the treatment of vascular trauma by the U.S. Secretary of Defense. For more information, visit www.Humacyte.com.

For uses other than the FDA approval in the extremity vascular trauma indication, the ATEV is an investigational product and has not been approved for sale by the FDA or any other regulatory agency.

Forward-Looking Statements

This press release contains forward-looking statements that are based on beliefs and assumptions and on information currently available. In some cases, you can identify forward-looking statements by the following words: “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties, and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. Although we believe that we have a reasonable basis for each forward-looking statement contained in this press release, we caution you that these statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. Forward-looking statements in this press release include, but are not limited to, our plans and ability to commercialize Symvess and, if approved by regulatory authorities, our product candidates, successfully and on our anticipated timelines; the degree of market acceptance of and the availability of third-party coverage and reimbursement for Symvess and, if approved by regulatory authorities, our product candidates; our ability to manufacture Symvess and, if approved by regulatory authorities, our product candidates in sufficient quantities to satisfy our clinical trial and commercial needs; the anticipated benefits of our ATEVs relative to existing alternatives; our plans and ability to execute product development, process development and preclinical development efforts successfully and on our anticipated timelines; our ability to design, initiate and successfully complete clinical trials and other studies for our product candidates and our plans and expectations regarding our ongoing or planned clinical trials; the anticipated characteristics and performance of our ATEVs; the implementation of our business model and strategic plans for our business; our ability to execute and achieve the expected benefits of our cost-saving measures and whether our efforts will result in further actions or additional asset impairment charges that adversely affect our business; and the timing or likelihood of regulatory filings, acceptances and approvals. We cannot assure you that the forward-looking statements in this press release will prove to be accurate. These forward-looking statements are subject to a number of significant risks and uncertainties that could cause actual results to differ materially from expected results, including, among others, changes in applicable laws or regulations, the possibility that Humacyte may be adversely affected by other economic, business, competitive and/or reputational factors, and other risks and uncertainties, including those described under the header “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2024 and Form 10-Q for the quarter ended September 30, 2025, each filed by Humacyte with the SEC, and in future SEC filings. Most of these factors are outside of Humacyte’s control and are difficult to predict. Furthermore, if the forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame, or at all. Except as required by law, we have no current intention of updating any of the forward-looking statements in this press release. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release.

Humacyte Investor Contact:
Joyce Allaire
LifeSci Advisors LLC
+1-617-435-6602
jallaire@lifesciadvisors.com 
investors@humacyte.com 

Humacyte Media Contact:
Rich Luchette
Precision Strategies
+1-202-845-3924
rich@precisionstrategies.com 
media@humacyte.com

FAQ

When will Humacyte (HUMA) present ATEV clinical data at VEITHsymposium 2025?

Humacyte has six presentations scheduled at VEITHsymposium on November 19 and November 20, 2025.

Which Humacyte (HUMA) presentation covers two-year outcomes versus autologous vein grafts?

The November 19 podium session presents "Human Acellular Vessels vs. Autologous Vein Grafts: Two-Year Outcomes from the War in Ukraine."

Does Humacyte (HUMA) present randomized trial results at VEITHsymposium 2025?

Yes; a November 19 presentation covers two-year outcomes in female patients from a prospective randomized trial comparing ATEV and autologous arteriovenous fistula for hemodialysis.

What CLN-PRO-V005 data will Humacyte (HUMA) present at VEITHsymposium 2025?

Humacyte will present CLN-PRO-V005 case reports on torso arterial trauma and a case series on DRIL procedures for dialysis access-associated steal syndrome on November 19, 2025.

Will Humacyte (HUMA) present long-term tissue regeneration data for ATEV at VEITHsymposium 2025?

Yes; a November 19 presentation covers histologic evaluation of ATEV after long-term clinical use, addressing in vivo regeneration of bioengineered blood vessels.

Where and when is the 52nd VEITHsymposium where Humacyte (HUMA) will present?

The VEITHsymposium takes place in New York, NY, November 18-22, 2025, with Humacyte presentations on November 19 and 20.